Online inquiry

IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8682MR)

This product GTTS-WQ8682MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets F3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001178096.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2152
UniProt ID P13726
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8682MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9260MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ4197MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ14663MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ8917MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ3305MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ13986MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ1622MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-910
GTTS-WQ7008MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA F-627
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW